Please login to the form below

Not currently logged in
Email:
Password:

Lilly exploring diabetes portfolio for Alzheimer's potential

Undertakes pre-clinical investigations as it monitors the area

Eli Lilly HQ 

Lilly is considering whether any of its diabetes drugs could be repositioned for additional uses to treat Alzheimer's disease and has begun some preliminary investigations of the area.

The company told PMLiVE that, although the work is a long way behind its focus on the 'amyloid hypothesis' and role of the Tau protein, the potential of diabetes drugs is “an area we are monitoring and interested in”.

“We're certainly doing some preclinical investigation of the potential of that kind of approach,” Lilly's chief scientific officer for neuroscience Dr Mike Hutton told PMLiVE.

Earlier this year the US National Institutes of Health (NIH) detailed its support for six Alzheimer's research projects, including one that uses computational methods to determine if existing drugs for other conditions can be used to treat the disease.

Meanwhile, diabetes drugs such as Takeda's Actos (pioglitazone) and Novo Nordisk's glucagon-like peptide-1 (GLP-1) Victoza (liraglutide) are being assessed for their potential in Alzheimer's.

“It's an interesting hypothesis,” said Dr Hutton. “The notion that diabetes and insulin resistance is potentially a risk factor for Alzheimer's has been around for a little while, and there is some data to support it.

“I think we'll have to wait and see just how reliable those observations are - right now it's just a bit too early to say.”

Despite noting the very early-stage of the work, Dr Hutton said discussions had taken place with his colleagues in diabetes about how their molecules might be applied to Alzheimer's disease.

“We've got a lot of interest in GLP-1, for example, as a way to potentially target the insulin resistance that's claimed to be a risk factor for, or a potential driver of, Alzheimer's disease pathology. That's really where we're looking and considering whether we would want to investigate that area.”

Lilly's GLP-1 hopes currently rest on its once-weekly drug dulaglutide, regulatory filings of which are expected later this year in diabetes, supported by strong phase III results.

• Read the full interview with Lilly's Dr Mike Hutton in the November issue of PME

Article by
Dominic Tyer

20th November 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Medical Communications

dna: as different as you. Every patient, disease and therapy is di­fferent. As is every message, stakeholder and educational challenge....

Latest intelligence

More of the same: The importance of strategic communications planning for biosimilar entry
GCI Health's Hannah Morris considers the importance of strategic communications planning for biosimilar entry, a market anticipated to deliver between €8-26bn in savings across the European Union by 2020....
Online Physician Communities
How can pharma realise the power of digital?
Firstly, by making it owned and driven by the most senior leadership team in the business...
Remapping the market: Does Pharma's global model need a shake up?
For patients, carers and professionals, wherever they are in the world, digital technology is inherent in their everyday lives. Digital is, so to speak, a global language. The success of...